Global Pets NSAIDs Market Growth 2025-2031

Publication ID:

LPI03257513

Publication Date:

March 4, 2025

Pages:

112

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Pets NSAIDs market size is predicted to grow from US$ 484 million in 2025 to US$ 691 million in 2031; it is expected to grow at a CAGR of 6.1% from 2025 to 2031.
Veterinary nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to control fever, pain, and other signs of inflammation in animals. Inflammation is the body"s response to irritation or injury and results in redness, warmth, swelling, and pain in the inflamed area.
According to Our PET Supplies Research Center, the global pet industry reached $ 261 billion in 2022, a year-on-year increase of 11.3%. The United States gains the highest pet penetration rate and becomes the largest pet market. According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales was about US$136.8 billion, an increase of 10.8% over 2021. According to IVH, the German pet products industry association, the number of pets in Germany reached 33.4 million in 2022, with a total turnover of nearly 鈧�6.5 billion. The 2023 China Pet Industry Trend Insight White Paper released by JD shows that the market size of the four major pet physical commodities is increasing year by year: pet supplies account for 45%, pet staple food accounts for nearly 35%, pet snacks account for 12%, and pet medicine and health care account for 43%.
The 鈥淧ets NSAIDs Industry Forecast鈥� looks at past sales and reviews total world Pets NSAIDs sales in 2024, providing a comprehensive analysis by region and market sector of projected Pets NSAIDs sales for 2025 through 2031. With Pets NSAIDs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pets NSAIDs industry.
This Insight Report provides a comprehensive analysis of the global Pets NSAIDs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pets NSAIDs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Pets NSAIDs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pets NSAIDs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pets NSAIDs.
This report presents a comprehensive overview, market shares, and growth opportunities of Pets NSAIDs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection Type
Oral Type
Others
Segmentation by Application:
Pet Hospital
Pet Shop
Household Use
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Bayer
JandJ
GSK
Septodont
Roche
PerioChip
Mobic
Rimadyl
Vetprofen
Novox
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pets NSAIDs market?
What factors are driving Pets NSAIDs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pets NSAIDs market opportunities vary by end market size?
How does Pets NSAIDs break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pets NSAIDs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pets NSAIDs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pets NSAIDs by Country/Region, 2020, 2024 & 2031
2.2 Pets NSAIDs Segment by Type
2.2.1 Injection Type
2.2.2 Oral Type
2.2.3 Others
2.3 Pets NSAIDs Sales by Type
2.3.1 Global Pets NSAIDs Sales Market Share by Type (2020-2025)
2.3.2 Global Pets NSAIDs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pets NSAIDs Sale Price by Type (2020-2025)
2.4 Pets NSAIDs Segment by Application
2.4.1 Pet Hospital
2.4.2 Pet Shop
2.4.3 Household Use
2.5 Pets NSAIDs Sales by Application
2.5.1 Global Pets NSAIDs Sale Market Share by Application (2020-2025)
2.5.2 Global Pets NSAIDs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pets NSAIDs Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Pets NSAIDs Breakdown Data by Company
3.1.1 Global Pets NSAIDs Annual Sales by Company (2020-2025)
3.1.2 Global Pets NSAIDs Sales Market Share by Company (2020-2025)
3.2 Global Pets NSAIDs Annual Revenue by Company (2020-2025)
3.2.1 Global Pets NSAIDs Revenue by Company (2020-2025)
3.2.2 Global Pets NSAIDs Revenue Market Share by Company (2020-2025)
3.3 Global Pets NSAIDs Sale Price by Company
3.4 Key Manufacturers Pets NSAIDs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pets NSAIDs Product Location Distribution
3.4.2 Players Pets NSAIDs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Pets NSAIDs by Geographic Region
4.1 World Historic Pets NSAIDs Market Size by Geographic Region (2020-2025)
4.1.1 Global Pets NSAIDs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pets NSAIDs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pets NSAIDs Market Size by Country/Region (2020-2025)
4.2.1 Global Pets NSAIDs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pets NSAIDs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pets NSAIDs Sales Growth
4.4 APAC Pets NSAIDs Sales Growth
4.5 Europe Pets NSAIDs Sales Growth
4.6 Middle East & Africa Pets NSAIDs Sales Growth
5 Americas
5.1 Americas Pets NSAIDs Sales by Country
5.1.1 Americas Pets NSAIDs Sales by Country (2020-2025)
5.1.2 Americas Pets NSAIDs Revenue by Country (2020-2025)
5.2 Americas Pets NSAIDs Sales by Type (2020-2025)
5.3 Americas Pets NSAIDs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pets NSAIDs Sales by Region
6.1.1 APAC Pets NSAIDs Sales by Region (2020-2025)
6.1.2 APAC Pets NSAIDs Revenue by Region (2020-2025)
6.2 APAC Pets NSAIDs Sales by Type (2020-2025)
6.3 APAC Pets NSAIDs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Pets NSAIDs by Country
7.1.1 Europe Pets NSAIDs Sales by Country (2020-2025)
7.1.2 Europe Pets NSAIDs Revenue by Country (2020-2025)
7.2 Europe Pets NSAIDs Sales by Type (2020-2025)
7.3 Europe Pets NSAIDs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pets NSAIDs by Country
8.1.1 Middle East & Africa Pets NSAIDs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pets NSAIDs Revenue by Country (2020-2025)
8.2 Middle East & Africa Pets NSAIDs Sales by Type (2020-2025)
8.3 Middle East & Africa Pets NSAIDs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pets NSAIDs
10.3 Manufacturing Process Analysis of Pets NSAIDs
10.4 Industry Chain Structure of Pets NSAIDs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pets NSAIDs Distributors
11.3 Pets NSAIDs Customer
12 World Forecast Review for Pets NSAIDs by Geographic Region
12.1 Global Pets NSAIDs Market Size Forecast by Region
12.1.1 Global Pets NSAIDs Forecast by Region (2026-2031)
12.1.2 Global Pets NSAIDs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pets NSAIDs Forecast by Type (2026-2031)
12.7 Global Pets NSAIDs Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Pets NSAIDs Product Portfolios and Specifications
13.1.3 Merck Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Pets NSAIDs Product Portfolios and Specifications
13.2.3 Bayer Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 JandJ
13.3.1 JandJ Company Information
13.3.2 JandJ Pets NSAIDs Product Portfolios and Specifications
13.3.3 JandJ Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 JandJ Main Business Overview
13.3.5 JandJ Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Pets NSAIDs Product Portfolios and Specifications
13.4.3 GSK Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Septodont
13.5.1 Septodont Company Information
13.5.2 Septodont Pets NSAIDs Product Portfolios and Specifications
13.5.3 Septodont Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Septodont Main Business Overview
13.5.5 Septodont Latest Developments
13.6 Roche
13.6.1 Roche Company Information
13.6.2 Roche Pets NSAIDs Product Portfolios and Specifications
13.6.3 Roche Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Roche Main Business Overview
13.6.5 Roche Latest Developments
13.7 PerioChip
13.7.1 PerioChip Company Information
13.7.2 PerioChip Pets NSAIDs Product Portfolios and Specifications
13.7.3 PerioChip Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 PerioChip Main Business Overview
13.7.5 PerioChip Latest Developments
13.8 Mobic
13.8.1 Mobic Company Information
13.8.2 Mobic Pets NSAIDs Product Portfolios and Specifications
13.8.3 Mobic Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Mobic Main Business Overview
13.8.5 Mobic Latest Developments
13.9 Rimadyl
13.9.1 Rimadyl Company Information
13.9.2 Rimadyl Pets NSAIDs Product Portfolios and Specifications
13.9.3 Rimadyl Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Rimadyl Main Business Overview
13.9.5 Rimadyl Latest Developments
13.10 Vetprofen
13.10.1 Vetprofen Company Information
13.10.2 Vetprofen Pets NSAIDs Product Portfolios and Specifications
13.10.3 Vetprofen Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Vetprofen Main Business Overview
13.10.5 Vetprofen Latest Developments
13.11 Novox
13.11.1 Novox Company Information
13.11.2 Novox Pets NSAIDs Product Portfolios and Specifications
13.11.3 Novox Pets NSAIDs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Novox Main Business Overview
13.11.5 Novox Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂